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Procoagulant Microparticles in Dogs with Immune-Mediated
Hemolytic Anemia
L. Kidd, J. Geddings, Y. Hisada, M. Sueda, T. Concannon, T. Nichols, E. Merricks, and N. Mackman
Background: Studies of some human prothrombotic diseases suggest that phosphatidylserine-positive (PS+) and tissue
factor-positive (TF+) microparticles (MPs) might play a role in the pathogenesis of thrombosis or serve as biomarkers of
thrombotic risk.
Hypothesis/Objectives: To determine if circulating levels of PS+MP and procoagulant activity (PCA) associated with
PS+MPs and TF+ MPs are increased in dogs with IMHA.
Animals: Fifteen dogs with primary or secondary IMHA and 17 clinically healthy dogs.
Methods: Prospective case-controlled observational study. Circulating PS+MPs were measured by flow cytometry. PCA
associated with PS+MPs and TF+MPs was measured by thrombin and Factor Xa generating assays, respectively.
Results: Circulating numbers of PS+MPs were not significantly higher in dogs with IMHA [control median 251,000/lL
(36,992–1,141,250/lL); IMHA median 361,990/lL (21,766–47,650,600/lL) P = .30]. However, PS+MP PCA [control median
2.2 (0.0–16.8) nM PS eq; IMHA median 8.596, (0–49.33 nM PS eq) P = .01] and TF+MP PCA [control median 0.0,
(0.0–0.0 pg/mL); IMHA median 0.0; (0–22.34 pg/mL], P = .04) were increased. Intravascular hemolysis, which we showed
might increase PS+ and TF+MP PCA, was evident in 3 of 5 dogs with PS+MP PCA and 2 of 4 dogs with TF+MP PCA
higher than controls. Underlying disease in addition to IMHA was detected in 1 of 5 dogs with PS+PCA and 3 of 4 dogs
with TF+MP PCA higher than controls.
Conclusions and Clinical Importance: TF+ and PS+MP PCA is increased in some dogs with IMHA. Further studies that
determine if measuring TF+ and PS+ MP PCA can help identify dogs at risk for thrombosis are warranted.
Key words: Auto-immune hemolytic anemia; Hemolysis; Microvesicle; Phosphatidylserine; Procoagulant; Tissue factor.
Immune-mediated hemolytic anemia (IMHA) is animportant cause of illness and death in dogs.1
Thromboembolic disease is a common complication
that affects survival.1 Activation of platelets and coagu-
lation have been reported in dogs with IMHA, but the
mechanisms of thrombosis have not been thoroughly
investigated.1–4 Drugs targeting platelets or coagulation
have been used for thromboprophylaxis, although it is
not known which, if any, are effective.1 Studies using
individually adjusted doses (IAD) of unfractionated
heparin are encouraging.5 However, IAD heparin
requires monitoring of anti-Xa activity which can be
expensive and time consuming. No biomarkers that pre-
dict thrombotic risk in individual dogs have been identi-
fied to help determine which dogs should receive
thromboprophylaxis. Further research investigating
mechanisms of thrombosis might help identify therapeu-
tic agents that target pathologic pathways, and identify
clinically useful biomarkers.
Recent research suggests that circulating microparti-
cles (MPs) might play a role in pathologic thrombosis
or serve as biomarkers of thrombotic risk for several
diseases in people.6–17 MPs are derived from blebbing
of the plasma membrane of many cell types, and are
released upon cell activation or injury and cleared pri-
marily by the reticuloendothelial system.6,7,18,19 Activa-
tion and injury of cells also cause plasma membranes to
lose phospholipid asymmetry and expose anionic phos-
pholipids, such as phosphatidylserine (PS), on their sur-
face. PS exposure provides a negatively charged
docking site for tenase and prothrombinase complexes
of the coagulation cascade.20 Platelet MPs exposing PS
are 50- to 100-fold more procoagulant than activated
platelets.21
Some evidence suggests that PS-positive MPs
(PS+MPs) from platelets, RBCs, and other cells are
involved in the pathogenesis of thrombosis in hemolytic
and polycythemic disease states.12,22 Platelet MP
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IMHA immune-mediated hemolytic anemia
IVH intravascular hemolysis
PS phosphatidylserine
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numbers are elevated in dogs with IMHA; however, PS
exposure has not been examined.4 Damaged and senes-
cent RBCs also express PS on their surface and form
procoagulant MPs.9,23,24 Triggers for increased RBC
microvesiculation include complement attack and oxida-
tive injury, conditions that are present in dogs with
IMHA.6,25 In addition to expressing PS, RBC MPs
scavenge nitric oxide and impair vasodilation.26 Thus,
PS+MPs derived from red cells and platelets might
contribute to thrombosis in IMHA.
Tissue factor-positive MPs (TF+MPs) might also con-
tribute to thrombosis or act as markers of thrombotic
risk. Tissue factor is the primary cellular initiator of
blood coagulation. TF triggers thrombus formation by
activating the coagulation cascade.27,28 Circulating
TF+MP numbers and PCA are increased in some pro-
thrombotic inflammatory, neoplastic, and hemolytic dis-
eases in people.10,13,15,29 PCA induced by TF+MPs has
been associated with thrombosis in some studies of
human patients with sickle cell crisis and pancreatic
cancer.11,17 Factors that induce TF expression, includ-
ing proinflammatory cytokines, free heme, and hypoxia,
are present in IMHA.1,24,30,31 TF+MPs are released pri-
marily from activated monocytes, and cancer cells.6,17
Indeed, TF mRNA expression is increased and the con-
centration of cytokines associated with monocyte/mac-
rophage activation are elevated in blood from dogs with
IMHA.32,33 Therefore, TF+MPs might also be
increased. To date, there have been no studies on
TF+MPs in dogs with IMHA.
In addition to the possibility of increased produc-
tion of MPs because of the presence of hemolysis, plate-
let activation, and activation of TF-expressing cells,
therapies might also increase MP levels in dogs with
IMHA. For example, MP formation occurs during stor-
age of blood products.34,35 Some immunosuppressive
agents such as cyclosporine also increase MP forma-
tion.36 Splenectomy has been associated with increases
in circulating MPs, possibly because of decreased
clearance.37–39
The purpose of this pilot study was to determine if
circulating levels of PS+MP and PCA associated with
PS+ and TF+MPs are increased in dogs with IMHA.
Materials and Methods
Study Design
Prospective case-controlled observational study.
Study Population
Dogs presenting to a specialty referral hospital for evaluation
of hemolytic anemia were screened for IMHA. IMHA (primary or
secondary) was confirmed by documenting the presence of anemia
(Hct<33%) with spherocytosis, autoagglutination, or a positive
Coombs test. Medication history was noted at the time of enroll-
ment. Medical records were reviewed retrospectively for documen-
tation of underlying disease. For the control group, clinically
healthy control dogs were recruited from students and faculty of
Western University of Health Sciences College of Veterinary
Medicine. A lack of historical medical problems, normal physical
examination, and a lack of anticoagulant or antiplatelet medica-
tions were required for inclusion into the control group. This
study was approved by the Western University of Health Sciences
Institutional Animal Care and Use Committee. Written informed
owner consent was obtained for each dog.
Sample Acquisition and Handling
We found no difference in the number of PS+MP when 23- or
21-gauge (G) needles were used to draw blood from peripheral
veins in dogs. Briefly, venous blood was atraumatically drawn
from a peripheral vein (cephalic or lateral saphenous) with a 23-G
butterfly needle directly into a 1.8-mL vacutainer tube containing
3.2% sodium citrate for 5 healthy dogs. The procedure was
repeated with a 21-G butterfly needle using the opposite limb.
MPs were enumerated by flow cytometry. There was no difference
between PS+MP and formation (21-G 4,906+/ 1206; 23-G
2710+/ 1448 PS+ MPs/lL, P = .44). Therefore, 23-G needles
were used in the present study for the dog’s comfort.
Venous blood was atraumatically drawn from a peripheral vein
(cephalic or lateral saphenous) with a 23-G butterfly catheter
directly into two 1.8-mL vacutainer tubes containing 3.2% sodium
citrate. One sample was submitted to Antech Diagnostics for
CBC, coagulation (PT, PTT D-Dimer, and fibrinogen levels), and
heartworm (Dirofilaria immitis) antigen testing. The other sample
was transported to the laboratory with minimal agitation in an
upright position, transferred to microcentrifuge tubes and centri-
fuged at 2,500 9 g for 15 minutes at room temperature. The
supernatant was carefully removed so as not to disturb the buffy
coat and spun again at 2,500 g for 15 minutes. The MP containing
platelet-free plasma (PFP) was carefully removed leaving a small
amount (approximately 100 lL) of PFP and any remaining plate-
let pellet undisturbed. The collected PFP was immediately frozen
at 80°C. The time of blood sampling to processing was less than
1 hour. All samples were analyzed within 1 year of freezing.
This centrifugation protocol is currently recommended for
obtaining PFP for microparticle research in people.40 We verified
that this centrifugation protocol also effectively removes platelets
from dog blood by a highly sensitive platelet detection protocol.40
Two 1.8-mL vacutainer tubes containing 3.2% citrate were filled
with blood from the cephalic vein of each of 2 dogs with a 23-G
butterfly catheter. PFP was isolated by the above protocol, 500 lL
from each of the 4 PFP samples were placed in a disposable cham-
ber mounted with a filter card and spun at 350 g for 10 minutes
by using a Cytospin 2 centrifuge.a The supernatant was absorbed
by the filter card, and cells were deposited on the slide through a
hole in the filter paper. The 4 slides were stained with Giemsa, and
10 high-powered fields (1,0009) on each slide were examined for
platelets. The cytospin centrifugation and platelet enumeration
were performed by an experienced technologist (STAT VETERI-
NARY LABORATORY San Diego CA). No platelets were seen
on any field for any sample. Each of the 2 dogs had a normal cir-
culating platelet count (375,000 and 241,000 per lL of EDTA anti-
coagulated whole blood, respectively). This suggests that platelet
contamination in the samples used for microparticle detection was
minimal, and the protocol of 2 sequential 2,500 9 g spins for
15 minutes effectively removes platelets from canine blood.
Flow Cytometry
Thirty microliter of PFP was incubated with 10-lL Annexin V
(AnnV)-FITC (BD) for 30 minutes in the dark at room tempera-
ture. Plasma samples were diluted in 470-lL flow cytometry buffer
with or without calcium (140 mM NaCl, 10 mM Hepes, 5 mM
CaCl2) just before running. Guidelines defining MP populations in
dogs have not been determined. Therefore, the upper limit for the
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MP size gate was determined using Megamix beadsb and extended
slightly beyond 0.9 lM to avoid bisecting a uniform population
observed in some samples in accordance with the International
Society of Thrombosis and Hemostasis Guidelines for human MPs
(Fig 1).41 MPs were defined as AnnV+ events within the MP size
gate and counted using cytocount beadsc . Samples were analyzed
on a Stratedigm Ex1000d flow cytometer.
PCA Associated with PS+MP
Levels of thrombin generation associated with PS+MPs were
measured in PFP utilizing a PS capture and prothrombinase
complex chromogenic thrombin generation assay (Zymuphen
MP-Activity; Aniara) according to the manufacturer’s instruc-
tions (Fig 2). MP concentration was determined by generating
a standard curve using samples with known PS+MP concentra-
tions provided in the test kit and reported as nM PS
equivalents (eq).
PCA Associated with TF+MPs
Microparticles were pelleted from 100 lL of PFP (thawed on
ice) by centrifugation (20,000 9 g for 15 minutes at 4°C) and
washed twice with HBSA buffer as previously described.42,43 Total
Factor Xa (FXa) and TF-dependent FXa generation was deter-
mined by a chromogenic assay. In this assay, procoagulant activity
associated with generation of FXa is measured using a chromo-
genic FXa substrate after adding FVIIa and FX to the MPs
(Fig 3A). Antibody directed against TF is added to determine how
much of the activity is specifically generated by the presence of TF
in the sample (Fig 3B). The assay was performed as previously
described for human samples, with a slight modification for use
with canine blood.42,43 Specifically, 1 lg of goat IgGe or 1 lg
of goat polyclonal anti-human TF antibody were used in each
100-lL reaction volume comprised of 50-lL washed MPs and
50 lL of human FX and FVIIa (the final concentration of FX
was 150 nM and FVIIa was 4.88 nM). This substitution was made
because the mouse anti-human TF monoclonal antibody used in
the human assay did not inhibit PCA induced by canine TF in
preliminary experiments. However, we found that the goat poly-
clonal anti-human TF antibody at this concentration inhibits
60–100% of PCA associated with TF+MPs in platelet-rich plasma
or PFP isolated from canine whole blood incubated with LPS
in vitro (data not shown).
Generation of Hemolyzed Blood Samples
TF+MPs were generated by incubating 2 mL of whole blood
anticoagulated in 3.2% Na citrate with LPS (10 lg/mL,f) for
5 hours at 37°C.44 To hemolyze the samples, untreated or LPS-
activated whole blood was aspirated and flushed vigorously 5
times through a 26-G needle with a syringe. PS+MP and TF+MP
PCA were measured as described above.
Statistical Analysis
Comparisons of continuous variables were made using the
Mann-Whitney U-test. Comparisons of categorical variables were
made using the Fisher’s exact test. Bivariate correlations were
done using the Spearman Rho test. A paired t-test was used to test
for differences in MP formation because of needle size. Statistical
analyses were performed by the statistical software program.g
Results
Signalment and Medication History
Seventeen control and 15 dogs with IMHA were
included in the study. There was no difference in age
between the dogs with IMHA and control dogs
Fig 1. Microparticle (MP) gating strategy. MPs were defined as
PS-positive, MP-sized events. Megamix beads (red) are shown with
corresponding bead size indicated. The bead population is over-
layed on total events of an example dog plasma sample (black)
containing counting beads (blue). The MP size gate extended from
the minimum detection limit of the Stratedigm S1000Ex flow
cytometer (0.1–0.2 lm) until just above the 0.9-lm sized bead
population as described in Materials and Methods.
Fig 2. Detection of PCA associated with PS+MPs (Zymuphen
MP-Activity Aniara). PS+MPs are captured by streptavidin and
biotinylated annexin V (A5) bound to a well. FXa, FVa and pro-
thrombin (FII) are added. In the presence of PS, FXa-FVa acti-
vates prothrombin to thrombin (IIa), which in turn acts on a
chromogenic thrombin substrate. Absorbance is measured at
405 nm (A405). There is a direct relationship between the concen-
tration of phospholipids and thrombin generation.
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(control; median 4.0 range 0.25–11 years; IMHA; med-
ian 5.0 range 2–13 years; P = .14). There were 4 neu-
tered males, 10 spayed females, 1 intact female, and 2
intact males in the control group. There were 9 neutered
males, 4 spayed females, 1 intact female, and 1 intact
male in the IMHA group. There was no difference in
sex distribution between control and IMHA groups
(P = .16). There were 7 mixed breed dogs, 3 English
springer spaniels, 2 German shorthaired pointers, and 1
each of Pointer, Heeler, Australian cattle dog, rat terrier
and beagle dog in the control group. The IMHA group
consisted of 5 mixed breed dogs (2 were Cocker spaniel
mixes), 2 Cocker spaniels, and 1 each of the following
breeds; Bernese mountain dog, Dachshund, Labrador
retriever, Schnauzer, Maltese, Papillion, poodle, and
Welsh corgi.
Before sampling, 2 dogs with IMHA received 1 dose
of aspirin, 8 received dexamethasone or prednisone, and
4 received azathioprine. One dog received a transfusion
24 hours before sampling. Five had not received any
medication before sampling.
Underlying Disease Screening in Dogs with IMHA
All dogs were screened for infection with Dirofilaria
immitis as incentive to join the study. One of the 15
dogs with IMHA was occult antigen positive and
microfilaremic. Nine of 15 dogs had additional vector-
borne disease screening; 7 were tested for antibody to
Borrelia burgdorferi, 6 were tested for antibody to Ehrli-
chia canis and Rickettsia rickettsii, and 3 were tested
using PCR for circulating DNA from Anaplasma sp.,
Babesia sp., Bartonella sp., Ehrlichia sp., Mycoplasma
sp., Neorickettsia risticii, and Rickettsia rickettsii. All
tests were negative. Abdominal ultrasound was per-
formed in 8 of 15 dogs; 1 dog had a small focal liver
mass, 1 dog had evidence of hepatomegaly and mild
pancreatitis. One dog had mild bilateral adrenomegaly,
and a slightly enlarged gall bladder with echogenic deb-
ris in the lumen, 1 dog had mild gall bladder distension
with slight thickening of the gall bladder wall, and 1
had slightly decreased corticomedullary junction in both
kidneys and a small renal infarct. Abdominal ultra-
sound was unremarkable in 3 dogs. Stage C valvular
heart disease was diagnosed in 1 dog based on history,
thoracic radiographs, abdominal ultrasound, and echo-
cardiogram. Two additional dogs had unremarkable
thoracic radiographs.
Hematologic and Coagulation Variables
Results for CBC and coagulation testing were avail-
able for 13 of 15 dogs with IMHA and 17 control dogs.
The hematocrit was significantly lower, and total white
cell, neutrophil, and monocyte counts were significantly
higher in dogs with IMHA. There was no difference in
platelet or lymphocyte count between groups (Table 1).
PT and PTT were significantly longer, and fibrinogen
levels were significantly higher in dogs with IMHA.
There was no difference in frequency of increases in
D-dimer levels between the 2 groups (Table 1).
Circulating Microparticle Analysis
PS+MPs were enumerated in 14 of 15 IMHA dogs
and 17 of 17 control dogs by flow cytometry. The med-
ian number of PS+MPs was higher in dogs with IMHA
versus control dogs, although the difference was not sta-
tistically significant (control; median 251,000/lL range
36,992–1,141,250/lL; IMHA; median 361,990/lL, range
21,766–47,650,600/lL, P = .30) (Fig 4).
Dogs with IMHA had significantly elevated PS+PCA
(control; median 2.2, range 0–16.8 nM PS eq; IMHA;
median 8.596, range 0–49.33 nM PS eq, P = .01). This
difference was mostly attributable to high values in 3
dogs. Two additional dogs with IMHA had PS+PCA
A B
Fig 3. Detection of PCA associated with TF+MPs. (A) Total Xa PCA is measured by adding FVIIa, FX and control antibody to a well
containing MPs pelleted from PFP by high speed centrifugation. FXa is generated in the presence of TF because of activation of FX by
extrinsic tenase (TFVIIa). FXa then cleaves a chromogenic Xa substrate. Absorbance is read at 405 nm (A405) and compared to a stan-
dard curve. (B) TF-dependent PCA is determined by the replacement of control antibody with a TF-specific antibody.
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slightly higher than the control dogs (Fig 5). 3 IMHA
dogs with PS+MP PCA above controls had evidence
of intravascular hemolysis (IVH) (18.47, 41.48 and
49.07 nM PS eq).
Both total FXa generation and TF-dependent FXa
generation (TF+MP PCA) were significantly higher in
dogs with IMHA as compared to control dogs. None of
the control dogs had detectable total FXa generation
(median 0.0 range 0.0–0.0), whereas 5 of 15 dogs with
IMHA had detectable total Xa generation (median 0.0
range 0–22.3 pg/mL P = .02) (Fig 6A). None of the
control dogs had detectable TF+PCA (median 0.0 range
0.0–0.0), whereas 4 of 15 dogs with IMHA had
increased levels (median 0.0; range 0–22.34 pg/mL,
P = .04) (Fig 6B). All of the total FXa generation was
TF dependent for 1 dog and none of the total FXa gen-
eration was TF dependent for another. The other 3
dogs had both TF-dependent and TF-independent FXa
generation. The dog with the highest TF-dependent
activity associated with MPs was infected with Dirofilar-
ia immitus, was microfilaremic, and had IVH (22.34 pg/
mL). TF-dependent activity associated with MPs was
slightly elevated in a dog with suspected mild pancreati-
tis (0.074 pg/mL), and moderately increased in a dog
with bilateral adrenomegaly and a mildly enlarged gall
bladder who had received a transfusion (0.677 pg/mL).
No underlying disease was detected in the 4th dog with
elevated TF-dependent PCA (0.347 pg/mL), although
this dog had IVH.
We determined the effect of hemolysis on PCA asso-
ciated with PS+MP and TF+MPs. Mechanical hemoly-
sis increased basal PS+PCA in PFP derived from
LPS-treated whole blood (Fig 7A). Mechanical hemoly-
sis also augmented TF-dependent and TF-independent
FXa generation in the MP fraction isolated from LPS-
treated whole blood (Fig 7B,C).
For dogs with IMHA, total FXa generation and
TF-dependent FXa generation was not correlated with
red cell count, platelet count, white cell count, neutro-
phil count, monocyte count, or coagulation variables
(data not shown).
Posthoc analysis of dogs with IMHA receiving gluco-
corticoids versus those who did not reveal a difference
in PS+MPs PCA (glucocorticoids; n = 8, median 14.98,
range 2.18–49.33; no glucocorticoids; n = 7, median 3.6,
range 0–41.48; P = .12). Two of 4 dogs with increased
TF-dependent FXa generation had received glucocortic-
oids.
Table 1. Hematologic and coagulation variables in dogs with IMHA and control dogs.
Variable Control n = 17 Median (Range) IMHA n = 13 Median (Range) P Value
Hematocrit % 49 (34–55) 14 (7–23) .0001*
Platelet count 9 1000/lLa 235 (174–369) 250 (48–583) .06
WBC 9 1000/lL 7.4 (4.5–12.4) 22.1 (7.6–70.9) .0001*
Neutrophils 9 1000/lL 4.7 (2.7–7.8) 18.2 (5.9–53.2) .0001*
Lymphocytes 9 1000/lL 2.4 (1.0–4.0) 1.1 (0.3–6.9) .21
Monocytes 9 1000/lL 0.296 (0.124–680) 1.4 (0.2–8.5) .0005*
PT (reference range 8–12 s) 6.6 (6.0–7.4) 7.2 (6.1–10.9) .03*
APTTb (reference range 10–25 s) 10 (<10.0–12.4) 14.2 (10–23.6) .0001*
Fibrinogen (reference range 150–400 mg/dL) 159 (120–263) 580 (167–844) .0001*
Elevated D-dimer 1/17 2/13 .56
*Statistically significant difference.
aIn 4 control and 2 IMHA dogs, platelet count was estimated as “adequate”. A value of 250,000/lL was used for calculations in these samples.
bTwo control dogs had an APTT estimate of less than 10 seconds. These were assigned a value of 10 for calculations.
Fig 4. Flow cytometric enumeration of Annexin V binding circu-
lating MP in IMHA (n = 14) and control (n = 17) dogs. Data are
expressed as the number of events X 103/lL. The median is indi-
cated by the bars (P = .30).
Fig 5. PCA associated with PS+MPs in IMHA (n = 15) and con-
trol (n = 17) dogs. Data are expressed as nM PS equivalents (Eq).
The median is indicated by the bars (P = .01). *=statistically
significant.
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Discussion
In this study, we found that some dogs with IMHA
had increased PCA associated with PS+MPs and
TF+MPs. We did not determine the cellular origin of
MPs in this study. However, the pathophysiologic state
of dogs with IMHA would theoretically support forma-
tion of PS+MPs because of the presence of red cell
destruction and platelet activation; and TF+MPs
because of the presence of monocyte activation and
conditions supporting endothelial cell activation.1,4,33
No studies of MPs in people with IMHA have been
performed. However, there is some evidence MPs play a
role in the pathophysiology of thrombosis in other
inflammatory hemolytic diseases in people. Sickle cell
crisis is similar to IMHA in that it is associated with a
proinflammatory, hypercoaguable state, hemolysis,
endothelial dysfunction, and thrombosis.13,45 PS+MPs
derived from RBCs and platelets, and TF+MPs from
monocytes and endothelial cells are elevated during
sickle cell crisis.13,29 Increased PCA is associated with
both PS+MP and TF+MP in human patients with sickle
cell disease, and TF+MP PCA is associated with acute
chest syndrome in these human patients.11,29,39 How-
ever, TF+MPs are not increased in people with paroxys-
mal nocturnal hemoglobinuria.46 Therefore, generalized
conclusions about MPs and thrombotic risk in proin-
flammatory hemolytic disease cannot be made.
It is noteworthy that PS+MP PCA and TF+MP PCA
was above the control range in only 5 of 15 and 4 of 15
dogs with IMHA, respectively (Figs 5 and 6B). Not all
dogs with IMHA are in a hypercoagulable state or form
thromboemboli.1,2,47 Whether or not thrombosis is
more likely in a dog with increased MP PCA requires
further study.
In this study, we included dogs with both primary
and secondary IMHA and did not exclude dogs with
medical problems unrelated to IMHA. The dog with
the highest TF+MP PCA and modestly increased
PS+MP PCA was heartworm positive and microfilare-
mic. Mild and moderate increase in TF+MP PCA with-
out increase in PS+MP PCA was observed in 1 dog
A B
Fig 6. Tissue factor-associated PCA in IMHA (n = 15) and control dogs (n = 17). A) Total Xa MP PCA (P = .02). B) TF-dependent MP




Fig 7. The effect of hemolysis on PCA associated with PS+MP
and TF+MP. PS+MP PCA, TF-dependent and TF-independent
PCA were measured in PFP isolated from blood that was mechan-
ically hemolyzed in vitro after phlebotomy. Blood samples from
each of 3 dogs were assayed in triplicate. The mean PCA is repre-
sented by the bar. For the TF+MP PCA assays, whole blood was
incubated with LPS before hemolysis and PFP isolation as
described in Materials and Methods. (A) PS+ PCA in PFP from
mechanically hemolyzed and nonhemolyzed blood. (B) TF-depen-
dent and C) TF-independent PCA associated with the MP fraction
isolated from nonhemolyzed and mechanically hemolyzed blood.
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with mild pancreatitis, and 1 dog with bilateral adreno-
megaly and mild gall bladder enlargement, respectively.
Inflammation and endothelial damage are associated
with D. immitis and Wolbachia spp. infection and pan-
creatitis, and thrombosis is associated with heartworm
disease, pancreatitis, and hyperadrenocorticism.48–50
Therefore, underlying disease processes could have con-
tributed to MP formation in these dogs. No other dog
with PS+MP (n = 3) or TF+MP PCA (n = 1) higher
than the control range had evidence of underlying dis-
ease. However, the presence of undetected underlying
disease cannot be ruled out because the diagnostic work
up varied between dogs because of financial constraints
of the owner and clinician preference.
Three of 15 dogs with IMHA had evidence of IVH
based on the presence of marked hemoglobinemia. This
prevalence is consistent with other studies of dogs with
IMHA.51 Profound hemoglobinuria confirmed IVH in 1
dog. Urinalysis was not performed for the other 2. An
atraumatic phlebotomy protocol was utilized and hemo-
lysis was not observed in any control samples. There-
fore, iatrogenic hemolysis as a cause for the marked
hemoglobinemia is unlikely.
All of the dogs with IVH had increased PCA. Two of
them had TF+MP PCA and PS+ MP PCA higher than
the control range, whereas the other had elevated PS+
PCA only. There is a strong correlation between
intravascular hemolysis and levels of circulating MPs in
people with sickle cell disease.39 Furthermore, comple-
ment-mediated red cell destruction increases RBC
microvesiculation and PCA.52 In this study, we found
that mechanical hemolysis augmented both PS- and
TF-mediated PCA. Increased exposure of PS and other
negatively charged phospholipids that facilitate binding
of tenase (FIXa/FVIIIa) and prothrombinase (FXa/
FVa) complexes could explain the augmented activity
seen with hemolysis in these assays.52,53 Further study is
required to determine whether RBC membrane frag-
ments or MP formation associated with IVH facilitate
thrombosis in vivo.
Drug and other treatments might affect MP levels by
a number of mechanisms.34–36,38 We found no signifi-
cant increase in PS+MP PCA in the 8 dogs with IMHA
which had received glucocorticoids compared to the 7
who did not, but the sample size was small. Only 4 dogs
received azathioprine, 2 dogs received aspirin and 1 dog
received a transfusion before sampling. Therefore, lar-
ger studies are required to determine the effect of spe-
cific treatments on MP levels.
In contrast to PCA associated with PS+MPs, we did
not find a significant increase in PS+MP number by
flow cytometry in dogs with IMHA. This might be
explained by the fact that flow cytometry is less sensi-
tive in detecting small MPs than functional assays of
MP PCA.7,43,54 Importantly, most PCA associated with
MPs can be attributed to small MPs.55 In addition, 2 of
5 dogs with increased TF-independent FXa generation
did not have increased PS-associated PCA. This is con-
sistent with other studies suggesting phospholipids other
than PS play a role in PCA associated with mem-
branes.53 It is possible that PCA associated with
exposed phospholipids other than PS could augment
and increase PCA associated with PS+MPs, without an
observed increase in PS+MP number.
Several preanalytical variables affect formation of
MPs. The most important are delay between sample
collection and centrifugation, agitation of samples after
collection, and centrifugation speed.40 Substantial effort
was made to limit these and other preanalytical vari-
ables from affecting the results of this study. Most clini-
cal studies of MPs necessitate freezing of MPs before
analysis.40 Freeze/thawing can affect MP formation,
although these effects are more pronounced when plate-
let poor, rather than PFP samples are used.43,56 PFP
was used in this study, and control and IMHA samples
were treated identically. However, it is possible that
freeze/thawing might have affected MP number and
PCA values. Additional limitations of this study include
its small size, lack of comprehensive underlying disease
screening, and standardized treatment and monitoring
protocols. We also did not determine the cellular origin
of MPs. Therefore, conclusions regarding the potential
role of MPs in the pathophysiology of thrombosis in
idiopathic and secondary IMHA and whether they can
serve as markers for thrombotic risk cannot be made.
However, in this study we have demonstrated that some
dogs with IMHA have increased PCA associated with
PS+MPs and TF+MPs in peripheral blood. Based on
these results, larger studies with comprehensive underly-
ing disease screening and standardized medical treat-
ment to determine whether MPs can be used as markers
of thrombotic risk, and studies to determine the cellular
origin of MPs in dogs with IMHA are warranted.
Footnotes
a Shandon Southern Instruments, Inc., Sewickley, PA.
b Biocytex, Merseille, France
c Dako, CA
d Stratedigm, CA
e Santa Cruz Biotech Dallas TX
f Sigma Aldrich, St. Louis, MO
g Graphpad Prism Version 6.0 San Diego CA
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